AR116115A1 - Dimetil amino azetidina amidas como inhibidores de jak - Google Patents

Dimetil amino azetidina amidas como inhibidores de jak

Info

Publication number
AR116115A1
AR116115A1 ARP190102520A ARP190102520A AR116115A1 AR 116115 A1 AR116115 A1 AR 116115A1 AR P190102520 A ARP190102520 A AR P190102520A AR P190102520 A ARP190102520 A AR P190102520A AR 116115 A1 AR116115 A1 AR 116115A1
Authority
AR
Argentina
Prior art keywords
dimethyl amino
jak inhibitors
compounds
amino azetidine
amides
Prior art date
Application number
ARP190102520A
Other languages
English (en)
Inventor
Corbin Thompson
Cameron Smith
Daniel D Long
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of AR116115A1 publication Critical patent/AR116115A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Abstract

La presente provee compuestos de fórmula (1) en donde las variables se definen en la memoria descriptiva, o una sal farmacéuticamente aceptable de los mismos, que son útiles como inhibidores de la quinasa JAK. La presente también provee composiciones farmacéuticas que comprenden dichos compuestos y métodos para usar dichos compuestos para tratar enfermedades respiratorias. Reivindicación 1: Un compuesto de fórmula (1), caracterizado porque: n es 0, 1 ó 2; R¹ es C₁₋₃ alquilo; cada R² es en forma independiente C₁₋₃ alquilo; o una sal farmacéuticamente aceptable del mismo.
ARP190102520A 2018-09-04 2019-09-03 Dimetil amino azetidina amidas como inhibidores de jak AR116115A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862726562P 2018-09-04 2018-09-04

Publications (1)

Publication Number Publication Date
AR116115A1 true AR116115A1 (es) 2021-03-31

Family

ID=67982186

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102520A AR116115A1 (es) 2018-09-04 2019-09-03 Dimetil amino azetidina amidas como inhibidores de jak

Country Status (17)

Country Link
US (3) US10947229B2 (es)
EP (1) EP3837258B1 (es)
JP (2) JP7324836B2 (es)
KR (1) KR20210056381A (es)
CN (1) CN112739697B (es)
AR (1) AR116115A1 (es)
AU (1) AU2019336167A1 (es)
BR (1) BR112021004052A2 (es)
CL (1) CL2021000514A1 (es)
CO (1) CO2021002977A2 (es)
EA (1) EA202190681A1 (es)
IL (1) IL281146B2 (es)
MA (1) MA53229A (es)
MX (1) MX2021002521A (es)
SG (1) SG11202101734RA (es)
TW (1) TWI791886B (es)
WO (1) WO2020051105A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108349972B (zh) 2015-11-03 2021-06-08 施万生物制药研发Ip有限责任公司 用于治疗呼吸疾病的jak激酶抑制剂化合物
EA037748B1 (ru) 2017-03-09 2021-05-18 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Конденсированные имидазо-пиперидиновые ингибиторы jak
MX2021002273A (es) 2018-09-04 2021-05-27 Theravance Biopharma R&D Ip Llc Proceso para preparar inhibidores de las jak y productos intermedios de estos.
JP7324836B2 (ja) * 2018-09-04 2023-08-10 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋ阻害剤としてのジメチルアミノアゼチジンアミド
KR20210056380A (ko) 2018-09-04 2021-05-18 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제로서 5원 내지 7원 헤테로사이클릭 아마이드
TW202144343A (zh) * 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
EP4146202A1 (en) * 2020-05-08 2023-03-15 Theravance Biopharma R&D IP, LLC Method of treating a patient infected with a coronavirus with nezulcitinib
US20230021647A1 (en) * 2021-06-21 2023-01-26 Theravance Biopharma R&D Ip, Llc Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l
CN117813298A (zh) * 2021-06-25 2024-04-02 施万生物制药研发Ip有限责任公司 作为jak抑制剂的咪唑吲唑化合物
WO2023215478A1 (en) 2022-05-05 2023-11-09 Theravance Biopharma R&D Ip, Llc Nezulcitinib for delivery by nebulized oral inhalation
WO2023230236A1 (en) 2022-05-26 2023-11-30 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
CA2532800C (en) 2003-07-23 2013-06-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
JP5651681B2 (ja) 2009-04-03 2015-01-14 大日本住友製薬株式会社 代謝型グルタミン酸受容体５介在障害の治療のための化合物、およびその使用方法
LT3001903T (lt) 2009-12-21 2018-01-10 Samumed, Llc 1h-pirazolo[3,4-b]piridinai ir jų terapinis panaudojimas
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
ES2654051T3 (es) 2013-12-05 2018-02-12 Pfizer Inc. Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinil acrilamidas
MD20160121A2 (ro) 2014-05-14 2017-05-31 Pfizer Inc. Pirazolopiridine şi pirazolopirimidine
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
PT3371185T (pt) 2015-11-03 2020-12-28 Topivert Pharma Ltd Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase
EP3712152B1 (en) 2015-11-03 2021-01-13 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
CN108349972B (zh) 2015-11-03 2021-06-08 施万生物制药研发Ip有限责任公司 用于治疗呼吸疾病的jak激酶抑制剂化合物
EA037748B1 (ru) 2017-03-09 2021-05-18 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Конденсированные имидазо-пиперидиновые ингибиторы jak
US20180258546A1 (en) * 2017-03-09 2018-09-13 Lam Research Corporation Electroplating apparatus and methods utilizing independent control of impinging electrolyte
CN110573157B (zh) 2017-05-01 2023-04-04 施万生物制药研发Ip有限责任公司 使用jak抑制剂化合物的治疗方法
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CN110603255B (zh) 2017-05-01 2023-02-10 施万生物制药研发Ip有限责任公司 Jak抑制剂化合物的结晶型式
JP7324836B2 (ja) 2018-09-04 2023-08-10 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋ阻害剤としてのジメチルアミノアゼチジンアミド
MX2021002273A (es) 2018-09-04 2021-05-27 Theravance Biopharma R&D Ip Llc Proceso para preparar inhibidores de las jak y productos intermedios de estos.
KR20210056380A (ko) 2018-09-04 2021-05-18 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제로서 5원 내지 7원 헤테로사이클릭 아마이드
KR20210084512A (ko) 2018-10-29 2021-07-07 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제로서 2-아자비시클로 헥산 화합물
CN111606908B (zh) 2019-02-25 2021-08-24 河南迈英诺医药科技有限公司 Jak抑制剂化合物及其用途
SG11202109563WA (en) 2019-03-05 2021-09-29 Incyte Corp Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
CN112279848A (zh) 2019-07-25 2021-01-29 四川海思科制药有限公司 一种泛JAKs抑制剂及其用途
TW202144343A (zh) * 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
EP4146202A1 (en) * 2020-05-08 2023-03-15 Theravance Biopharma R&D IP, LLC Method of treating a patient infected with a coronavirus with nezulcitinib
US20230021647A1 (en) * 2021-06-21 2023-01-26 Theravance Biopharma R&D Ip, Llc Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l

Also Published As

Publication number Publication date
US20210155620A1 (en) 2021-05-27
MA53229A (fr) 2022-05-11
EP3837258A1 (en) 2021-06-23
CN112739697B (zh) 2023-10-20
IL281146B2 (en) 2023-12-01
EP3837258B1 (en) 2024-04-24
TW202024073A (zh) 2020-07-01
US10947229B2 (en) 2021-03-16
CN112739697A (zh) 2021-04-30
JP2021535177A (ja) 2021-12-16
AU2019336167A1 (en) 2021-03-11
IL281146B1 (en) 2023-08-01
BR112021004052A2 (pt) 2021-05-25
TWI791886B (zh) 2023-02-11
IL281146A (en) 2021-04-29
SG11202101734RA (en) 2021-03-30
US20230322774A1 (en) 2023-10-12
WO2020051105A1 (en) 2020-03-12
EA202190681A1 (ru) 2021-05-28
MX2021002521A (es) 2021-04-28
US20200071323A1 (en) 2020-03-05
JP7324836B2 (ja) 2023-08-10
CL2021000514A1 (es) 2021-07-23
US11634419B2 (en) 2023-04-25
KR20210056381A (ko) 2021-05-18
CO2021002977A2 (es) 2021-05-31
JP2022172299A (ja) 2022-11-15

Similar Documents

Publication Publication Date Title
AR116115A1 (es) Dimetil amino azetidina amidas como inhibidores de jak
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
CY1121062T1 (el) Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου alzheimer
CO2017004481A2 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
CO2019011809A2 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CO2017000399A2 (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
CY1118739T1 (el) Ενωσεις αμφι(φθoρoαλκυλ)-1,4-βενζoδιαζεπινoνης ως αναστολεις toy notch
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
EA201992126A1 (ru) Ингибиторы jak, содержащие 4-членный гетероциклический амид
CR20190124A (es) Inhibidores de ssao de aminopirimidina
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
EA201791576A1 (ru) Ингибитор jak
PE20151542A1 (es) Compuestos de tetrahidropirrolotiazina
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
CO2021002976A2 (es) Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak
AR113803A1 (es) Compuesto de pirimidina como inhibidor de jak quinasas
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
EA201990902A1 (ru) Ингибиторы тирозинкиназы брутона
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
UY36257A (es) “compuestos de imidazopiridazina”.
CY1122375T1 (el) Συμπυκνωμενα με τετραϋδροφουρανιο αμινοϋδροθειαζινικα αναλογα τα οποια ειναι χρησιμα στη θεραπεια της νοσου toy alzheimer
EA201990109A1 (ru) Митохондриальные ингибиторы для лечения пролиферативных нарушений
AR098319A1 (es) Profármacos de antagonista de nmda